Sinorda Pharmaceutical has formed a strategic partnership with Boteng Biotech to accelerate the development of cell therapy drugs for solid tumors.

On April 22, 2022, Guizhou Sinorda Pharmaceutical Co., Ltd. (hereinafter referred to as Sinorda Pharma) announced a strategic partnership with Suzhou Boteng Biopharmaceutical Co., Ltd. (hereinafter referred to as Boteng Bio). The two companies will establish a long-term, comprehensive strategic alliance focusing on areas such as cell therapy drug development, the establishment of cell and gene therapy R&D and manufacturing platforms, and international regulatory submissions.

Sinorda Pharma focuses on the research and development of innovative drugs targeting gastrointestinal diseases, cancer immunotherapy, and oncolytic virus therapies. The company already has multiple new drug projects in clinical stages and boasts experience in filing applications for both domestic and international-level novel medications. Its subsidiary, Jiangsu Tai Rui Sinorda Biopharmaceutical Technology Co., Ltd., offers robust capabilities in preclinical pharmacology and efficacy studies, as well as comprehensive clinical research services for oncology immunotherapies. Boteng Bio With an end-to-end gene and cell therapy CDMO service platform, covering areas such as plasmids, cell therapies, gene therapies, oncolytic viruses, nucleic acid therapies, and live bacterial therapies. 
 

According to the agreement, Boteng Bio will provide Sinorda Pharma with research and development services for the development, manufacturing, and regulatory approval of cell therapy products. Meanwhile, the two sides also reached an agreement on expanding their international business and will jointly move forward with this initiative. The establishment of Sweden's cell and gene R&D and manufacturing platform And International application for T-cell immunotherapy. Currently, the first collaborative project—SND002 Sentinel Lymph Node T-cell Anti-Tumor Injectable (Sentinel lymph node T cell, SLN-T)—has officially kicked off. The project has already received Phase II clinical trial approval from the European Union and was approved in 2013 to receive support under the national key science and technology program "Major New Drug Development." This strategic partnership will effectively integrate the resources and expertise of both parties, helping to reduce R&D costs, accelerate development timelines, and swiftly advance the creation of innovative new drugs.

"Sinorda Pharma has formed a strategic partnership with Boteng Bio, marking a milestone in advancing the development of innovative immunotherapy drugs for solid tumors, accelerating clinical research and regulatory submissions for its pipeline programs, and paving the way for international dual filings. Sinorda Pharma brings extensive expertise in immune cell and oncolytic virus R&D and treatment, coupled with robust clinical resources, cutting-edge technologies for tumor microenvironment and immune function assessment, as well as proven evaluation capabilities. Meanwhile, Boteng Bio boasts an end-to-end CDMO platform, deep project experience, unparalleled capabilities in scaling up drug production, and a seasoned, globally-minded team—solidifying its position as an industry leader. This collaboration is poised to play a pivotal role in driving both rapid near-term growth and long-term value creation."

—— Dr. Hu Pingsheng, Founder of Sinorda Pharmaceuticals 
 

“We are thrilled to establish a strategic partnership with Sinorda Pharma. Boteng Biologics’ end-to-end gene and cell therapy CDMO platform, along with its robust quality system, will empower Sinorda to swiftly and efficiently advance its R&D pipeline, accelerating the time-to-market for its cell-based therapeutic products. Sinorda Pharma boasts extensive experience in innovative drug development across China, the U.S., and Europe. This strategic collaboration will not only foster mutual growth but also drive the joint expansion of our international platforms, expediting the research, development, and commercialization of cutting-edge therapies—benefiting more patients at an earlier stage.”

— Dr. Wang Yangzhou, CEO of Boteng Biotech  

About Sinorda Pharmaceuticals

Guizhou Sinorda Pharmaceutical Co., Ltd. is focused on innovative drug research and development, as well as the industrialization of tumor immunotherapy. The company boasts robust capabilities in biopharmaceutical R&D, backed by an experienced technical and management team, along with extensive collaborative expertise in drug innovation and international partnerships across China, the U.S., and Europe—making it a pioneer in the field of tumor immunotherapy. The company currently holds a diverse pipeline of innovative drug candidates already in clinical stages. It has established comprehensive partnerships with renowned domestic and international pharmaceutical companies, research institutions, CROs, CMOs, and government agencies, fostering a collaborative ecosystem that maximizes resource sharing, leverages complementary strengths, and drives the development of highly competitive new therapies. Moving forward, Guizhou Sinorda Pharmaceutical Co., Ltd. is committed to advancing innovative drugs at lower costs and faster speeds, positioning itself as one of the industry’s most promising and value-driven enterprises in the field of drug innovation. 
 

About Boteng Bio

Suzhou Boteng Biopharmaceutical Co., Ltd. was established in December 2018, based in Suzhou Industrial Park. Relying on its parent company—Chongqing Boteng Pharmaceutical Technology Co., Ltd. (stock code: 300363)—the company has built CDMO platforms covering plasmids, cell therapy, gene therapy, oncolytic viruses, nucleic acid therapies, and live bacterial therapies. It offers end-to-end services ranging from library construction to the development of manufacturing and analytical methods, cGMP-compliant production, and even formulation filling. These services span across various drug development stages, including early-stage research, investigator-initiated clinical trials, Investigational New Drug (IND) applications, registration clinical trials, and ultimately, commercial-scale production—helping clients accelerate their drug development and time-to-market processes.